Drug Trial Radar · NCT04053270
Multicentre Phase III Erythropoietic Protoporphyria Study
Last checked: Nov 20, 2026Latest source record: Oct 10, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
May 2007
Primary completion
Dec 9, 2009
Study completion Dec 9, 2009
Sponsor
- Lead sponsor
- Clinuvel Pharmaceuticals LimitedIndustry
- Sponsor type
- Industry
- First posted
- Aug 12, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a phase III, multicentre, randomised, double-blind, placebo-controlled study, to evaluate the safety and efficacy of subcutaneous bioresorbable afamelanotide implants in patients with Erythropoietic Protoporphyria (EPP). The study was conducted with two parallel study arms with crossover between treatments every 60 days. Eligible patients were randomised to a treatment group, and received implants of active treatment (afamelanotide 16mg) or placebo, in an alternating crossover fashion according to the following dosing regime: * Group A was administered active implants on Days 0, 120, 240 and placebo implants on Days 60, 180, 300 * Group B was administered placebo implants on Days 0, 120, 240 and active implants on Days 60, 180, 300
Conditions
- Erythropoietic Protoporphyria
Interventions
AfamelanotideDrug
16mg subcutaneous implant
PlaceboDrug
Placebo subcutaneous implant
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative Number of Days of Phototoxic Reactions (Study Efficacy Population)Time frame: 0-360 days or Early Termination
- The Mean Number of Phototoxic Reactions (Study Efficacy Population)Time frame: 0-360 days or Early Termination
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.